Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders
Serna, Ángel (Vall d'Hebron Institut d'Oncologia)
Navarro Garcés, Víctor (Vall d'Hebron Institut d'Oncologia)
Jiménez, Moraima (Vall d'Hebron Institut d'Oncologia)
Iraola-Truchuelo, Josu (Vall d'Hebron Institut d'Oncologia)
Bosch, Marc (Vall d'Hebron Institut d'Oncologia)
García, Cristina (Vall d'Hebron Institut d'Oncologia)
Falcó Roget, Anna (Vall d'Hebron Institut d'Oncologia)
Albasanz, Adaia (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Ruiz-Camps, Isabel (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Andrés, Cristina (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Antón Pagarolas, Andrés, 1976- 1976- (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Esperalba, Juliana (Hospital Universitari Vall d'Hebron. Institut de Recerca)
Ferrero, Ainara (Hospital Arnau de Vilanova (Lleida, Catalunya))
García González, Tomas (Hospital Arnau de Vilanova (Lleida, Catalunya))
Carpio Segura, Cecilia del Carmen (Vall d'Hebron Institut d'Oncologia)
Crespo, Marta (Vall d'Hebron Institut d'Oncologia)
Iacoboni, Gloria (Vall d'Hebron Institut d'Oncologia)
Marín-Niebla, Ana (Vall d'Hebron Institut d'Oncologia)
Bosch Albareda, Francesc 1947- (Universitat Autònoma de Barcelona. Departament de Medicina)
Abrisqueta, Pau (Universitat Autònoma de Barcelona. Departament de Medicina)

Data:	2025
Resum:	Despite advances in vaccination and the use of antiviral treatments, patients with hematologic malignancies, including B-cell lymphoproliferative disorders, are particularly vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The recent introduction of bispecific antibodies (BsAbs) in the treatment algorithm of relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL) has raised concerns regarding their impact on COVID-19 outcomes. This study aimed to evaluate the impact of SARS-CoV-2 infection on treatment outcomes in patients receiving BsAbs. We assessed the severity of COVID-19 and SARS-CoV-2 serostatus, with antibody titers measured before, during, and after BsAbs administration. A total of 109 patients with B-NHL treated with BsAbs from March 2020 to January 2023 were included. SARS-CoV-2 infection was observed in 56 patients (51%), with 36% experiencing prolonged viral shedding, causing therapy delays in 78% of patients and permanent discontinuations in 19%. Regarding COVID-19 severity, 36% of patients presented moderate, 20% severe, and 12% critical disease. Seven patients (13%) died owing to COVID-19 pneumonia. Similar to observations with anti-CD20 monoclonal antibodies, BsAbs were associated with negative antispike serostatus for at least 6 months after treatment completion. Importantly, this lack of seroconversion was linked with severe disease and increased mortality. These findings underscore important considerations for the management of patients receiving BsAbs.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	Blood advances, Vol. 9 Núm. 16 (August 2025) , p. 4180-4189, ISSN 2473-9537

DOI: 10.1182/bloodadvances.2024015406
PMID: 40402079

10 p, 827.2 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats